459 results on '"Nguyen, Mindie H."'
Search Results
2. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis
3. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study
4. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation
5. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
6. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
7. Su1551 CLINICAL PRESENTATION AND SURVIVAL IN MALE COMPARED TO FEMALE PATIENTS WITH CIRRHOSIS: A LONG-TERM COHORT STUDY OF 13,228 REAL-WORLD PATIENTS
8. 328: REAL-WORLD TREATMENT OUTCOME WITH PROTEASE INHIBITOR (PI) VS NON-PI DIRECT ACTING ANTIVIRALS (DAAS) IN DECOMPENSATED HCV CIRRHOSIS: A REAL-C STUDY
9. 868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
10. Sa1396: ANTIVIRAL THERAPY IMPROVES SURVIVAL IN VIRAL-ASSOCIATED HEPATOCELLULAR CARCINOMA AFTER LIVER RESECTION BUT IS SEVERELY UNDERUTILIZED
11. 949: PROGNOSTIC LIVER SECRETOME SIGNATURE AND ALPHA-FETOPROTEIN (PLSEC-AFP) PREDICTS LONG-TERM HEPATOCELLULAR CARCINOMA RISK IN PATIENTS WITH CIRRHOSIS: A NATIONWIDE PHASE 3 BIOMARKER STUDY IN THE U.S.
12. Su1339: SEX DIFFERENCES IN VIROLOGIC (VR), BIOCHEMICAL (BR), COMPLETE RESPONSE (CR) AND HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE AMONG PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH NUCLEOS(T)IDES (NUC): A MULTICENTER LONGITUDINAL STUDY
13. Mo1336: PREVALENCE AND MORTALITY OF ALCOHOL-RELATED LIVER DISEASES DURING COVID-19 PANDEMIC
14. Su1396: DIFFERENTIAL CLINICAL PRESENTATIONS AND OUTCOMES AMONG U.S. PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) BY RACE AND ETHNICITY: A LONGITUDINAL STUDY
15. Tu1556 TRENDS AND FORECAST MORTALITY OF LIVER CANCER TO 2040 IN THE UNITED STATES: A POPULATION-BASED STUDY
16. Su1619 PREVALENCE AND MORTALITY OF NAFLD, MAFLD, AND MASLD IN THE UNITED STATES FROM 1988-2019: A POPULATION-BASED ANALYSIS
17. Su1587 SUBOPTIMAL ASSESSMENT OF FIBROSIS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PRIMARY CARE VERSUS LIVER CLINIC SETTINGS
18. Su1593 LIVER AND NON-LIVER OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) VERSUS MASLD WITH INCREASED ALCOHOL USE (METALD) STRATIFIED BY PRESENCE OF VIRAL HEPATITIS: A STUDY OF 850,156 REAL-WORLD PATIENTS IN THE U.S.
19. Su1555 ASSOCIATION BETWEEN REDUCED LIVER AND NON-LIVER MORTALITY AND BARIATRIC SURGERY IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)-RELATED LIVER CIRRHOSIS – IMPACT OF SURGICAL APPROACH, 2005-2019
20. Sa1661 LATE DIAGNOSIS OF CHRONIC HEPATITIS B IN THE UNITED STATES: A POPULATION-BASED RETROSPECTIVE ANALYSIS
21. Sa1652 PRO-C3, GP73 AND THEIR COMBINATION ACCURATELY ASSESS SIGNIFICANT AND ADVANCED FIBROSIS IN CHRONIC HEPATITIS B PATIENTS
22. Sa1637 PREVALENCE OF HEPATITIS B (HBV) VACCINE-INDUCED IMMUNITY ON LONG-TERM FOLLOW-UP AND OF ANAMNESTIC RESPONSE FOLLOWING VACCINE BOOSTER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 91 STUDIES, 208 COHORTS, AND 190,693 PERSONS
23. Sa1633 ASSOCIATION AND RISK STRATIFICATION OF METABOLIC RISK FACTORS ON LIVER AND NON-LIVER COMPLICATIONS IN CHRONIC HEPATITIS B: A NATIONWIDE U.S. STUDY
24. Sa1616 MORTALITY RATES AMONG PATIENTS SUCCESSFULLY TREATED FOR HEPATITIS C: A REAL WORLD MULTINATIONAL COHORT STUDY
25. Sa1631 PERICOMPLICATION DIAGNOSIS OF HEPATITIS C INFECTION–RESULTS OF A NATIONWIDE U.S. STUDY
26. Sa1619 CHANGES IN LIVER DISEASE ETIOLOGY AND RACIAL ETHNIC MAKE-UP OF PERSONS WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: A MODELING STUDY BASED ON THE SEER-MEDICARE DATABASE
27. Sa1606 SEVERE UNDERUTILIZATION OF PALLIATIVE/HOSPICE CARE AND DISCUSSION AMONG PATIENTS WITH CIRRHOSIS INCLUDING THOSE WITH DECOMPENSATION AND HCC: FINDINGS FROM A SINGLE-CENTER REAL-WORLD STUDY OF 15.876 PATIENTS
28. 1052 PAAM FOR HEPATOCELLULAR CARCINOMA RISK STRATIFICATION IN PATIENTS WITH CIRRHOSIS: MULTICENTER PHASE 3 BIOMARKER VALIDATION STUDIES IN THE U.S.
29. 1060 EPIDEMIOLOGY, NATURAL HISTORY, AND TREATMENT OUTCOMES OF PREGNANT WOMEN WITH HCV INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 227 STUDIES AND 255,862,858 WOMEN
30. α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma
31. 507 NATURAL HISTORY AND HEPATOCELLULAR CARCINOMA RISK IN UNTREATED CHRONIC HEPATITIS B PATIENTS WITH INDETERMINATE PHASE
32. 658 LIVER COMPLICATIONS IN UNTREATED TREATMENT-INELIGIBLE VERSUS TREATED TREATENT-ELIGIBLE PATIENTS WITH HEPATITIS B
33. 510 PROGRESSION OF CHRONIC HEPATITIS B TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA BY AGE, SEX, DISEASE ACTIVITY, AND TREATMENT STATUS USING AASLD CRITERIA
34. Tu1551 COST-EFFECTIVENESS OF HEPATOCELLULAR CARCINOMA SURVEILLANCE PROGRAMS USING MULTI-TARGET BLOOD TEST
35. Tu1548 CHEMOPREVENTION OF HEPATOCELLULAR CARCINOMA WITH STATINS, ASPIRIN AND METFORMIN: SYSTEMATIC REVIEW AND META-ANALYSIS OF MATCHED STUDIES
36. Tu1544 CHANGES OVER TIME IN THE CHARACTERISTICS AND SURVIVAL RATES OF HEPATOCELLULAR CARCINOMA IN A NATIONWIDE COHORT OF REAL-WORLD U.S. PATIENTS, 2003–2021
37. Mo1602 USE AND OUTCOMES OF HEPATITIS B VIRUS POSITIVE GRAFTS FOR RENAL OR HEART TRANSPLANTATION IN THE US (1999-2021)
38. Mo1527 VIROLOGIC (VR), BIOCHEMICAL (BR), COMPLETE RESPONSE (CR) AND HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE AMONG MALE AND FEMALE PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH NUCLEOS(T)IDES (NUC): A REAL-B STUDY
39. Sa1578 NATURAL HISTORY OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG REAL-WORLD PATIENTS
40. Sa1552 ETHNIC DIFFERENCES IN LIVER AND MORTALITY OUTCOMES OF NONALCOHOLIC FATTY LIVER DISEASE: A REAL-WORLD STUDY WITH LONGITUDINAL FOLLOW-UP
41. 816 RACIAL AND ETHNIC DISPARITIES IN DIRECT-ACTING ANTIVIRAL (DAA) TREATMENT AND SURVIVAL OUTCOMES FOR TREATED/SVR (SUSTAINED VIROLOGIC RESPONSE) AND UNTREATED/NON-SVR PATIENTS WITH HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA (HCV-HCC): A REAL-HCC STUDY
42. 815 LONG-TERM OUTCOMES IN LIVER TRANSPLANT RECIPIENTS WITH DONOR-DERIVED HEPATITIS-C INFECTION
43. Mo1492 PREVALENCE OF NON-LIVER COMORBIDITIES, MODETATE/SEVERE STEATOSIS, NASH AND LIVER FIBROSIS IN ASIAN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): A SYSTEMIC REVIEW AND META-ANALYSIS OF 128 STUDIES
44. Tu1626 OUTCOMES OF PATIENTS REFERRED TO A TRANSPLANT CENTER FOR URGENT LIVER TRANSPLANTATION EVALUATION
45. Tu1622 LIVER TRANSPLANT RECIPIENTS WITH ALCOHOL-RELATED LIVER DISEASE AND LIMITED SOBRIETY CAN ACHIEVE EXCELLENT POST-TRANSPLANT OUTCOMES USING A SYSTEMATICALLY DERIVED MULTIDISCIPLINARY PROTOCOL
46. Mo1515 DEVELOPMENT AND REGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OVERALL AND IN SELECTED PATIENT COHORTS: A META-ANALYSIS OF 32 LONGITUDINAL STUDIES AND 179,398 ASIAN PATIENTS
47. Sa1520 DECREASED HEPATITIS B IMMUNITY IN CHILDREN AND ADOLESCENTS AND ANAMNESTIC RESPONSE TO BOOSTER VACCINATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
48. Mo1485 A META-ANALYSIS OF MORTALITY AND NON-LIVER COMORBIDITY OUTCOMES IN ASIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) - POOL ESTIMATES FROM 29 STUDIES AND 725,573 PATIENTS
49. Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial
50. Reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.